65 related articles for article (PubMed ID: 19798634)
1. The assessment of human regional drug absorption of free acid and sodium salt forms of acipimox, in healthy volunteers, to direct modified release formulation strategy.
Menon R; Cefali E; Wilding I; Wray H; Connor A
Biopharm Drug Dispos; 2009 Dec; 30(9):508-16. PubMed ID: 19798634
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers.
Martin NE; Collison KR; Martin LL; Tardif S; Wilding I; Wray H; Barrett JS
J Clin Pharmacol; 2003 May; 43(5):529-38. PubMed ID: 12751274
[TBL] [Abstract][Full Text] [Related]
3. An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat.
Connor A; Evans P; Doto J; Ellis C; Martin DE
J Clin Pharmacol; 2009 May; 49(5):606-12. PubMed ID: 19304891
[TBL] [Abstract][Full Text] [Related]
4. [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
Yang XG; Nie SF; Bai HJ; Zhang GJ; Pan WS
Yao Xue Xue Bao; 2005 May; 40(5):457-61. PubMed ID: 16220793
[TBL] [Abstract][Full Text] [Related]
5. Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible.
Reddy MB; Connor A; Brennan BJ; Morcos PN; Zhou A; McLawhon P; Fretland A; Evans P; Smith P; Tran JQ
Biopharm Drug Dispos; 2011 Jul; 32(5):261-75. PubMed ID: 21660978
[TBL] [Abstract][Full Text] [Related]
6. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.
Zhu T; Ansquer JC; Kelly MT; Sleep DJ; Pradhan RS
J Clin Pharmacol; 2010 Aug; 50(8):914-21. PubMed ID: 20145261
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of acipimox and of its N-deoxy metabolite following single and repeated oral administration to healthy volunteers.
Efthymiopoulos C; Strolin Benedetti M; Poggesi I; Ruff F; Basileo G; Musatti L
Therapie; 1993; 48(1):23-6. PubMed ID: 8356541
[TBL] [Abstract][Full Text] [Related]
9. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
11. Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover study.
Tsunashima D; Kawamura A; Murakami M; Sawamoto T; Undre N; Brown M; Groenewoud A; Keirns JJ; Holman J; Connor A; Wylde H; Wilding I; Ogawara K; Sako K; Higaki K; First R
Clin Ther; 2014 May; 36(5):748-59. PubMed ID: 24680768
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
Wangemann M; Retzow A; Vens-Cappell B
Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
[TBL] [Abstract][Full Text] [Related]
13. A study on the relative bioavailability of a sustained-release formulation of diclofenac sodium.
Suleiman MS; Najib N; el-Sayed Y; Hasan M; Abdulahameed M
Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):276-9. PubMed ID: 2737796
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
[TBL] [Abstract][Full Text] [Related]
15. Biopharmaceutic approach in designing a controlled release tablet of sodium monofluoro phosphate. Characterization of absorption sites and evaluation of modified dosage form.
Vattikonda CS; Ritschel WA; Herbert C
Int J Clin Pharmacol Ther; 1994 Oct; 32(10):559-66. PubMed ID: 7834164
[TBL] [Abstract][Full Text] [Related]
16. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
Guivarc'h PH; Vachon MG; Fordyce D
Clin Ther; 2004 Sep; 26(9):1456-69. PubMed ID: 15531008
[TBL] [Abstract][Full Text] [Related]
17. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Reed RC; Cavanaugh JH
J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: an open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers.
Piñeyro-López A; Pineyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez Silva M; Wacksman N; Lujàn Rangel R; de Lago A; Trejo D; Gonzàlez-de la Parra M; Namur S
Clin Ther; 2006 Jan; 28(1):110-5. PubMed ID: 16490584
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance.
Weinling E; McDougall S; Andre F; Bianchetti G; Dubruc C
Fundam Clin Pharmacol; 2006 Aug; 20(4):397-403. PubMed ID: 16867025
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
Dulac O; Alvarez JC
Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
